DLG5与34βE12在乳腺癌中表达的相关性及临床意义

Relationship and clinical significance of DLG5 and 34βE12 in breast cancer

目的:探讨细胞极性蛋白DLG5与高分子量角蛋白(34βE12)在乳腺癌中表达的相关性,阐明其在乳腺癌临床诊断中的作用。方法:收集乳腺癌组织,通过免疫组织化学(immunohistochemistry,IHC)分析DLG5的表达情况,以及其与34βE12表达的相关性。利用慢病毒技术敲低DLG5的表达后,Western blot检测DLG5与34βE12的表达。结果:DLG5的表达随乳腺癌恶性程度增加而降低,与雌激素受体/孕激素受体(ER/PR)、34βE12的表达呈现正相关性。在乳腺上皮细胞MCF10A中,敲低DLG5表达后,34βE12的表达显著降低。结论:在乳腺癌中,DLG5可以用于早期诊断、恶性程度判定,并且可以作为ER/PR阳性乳腺癌治疗及预测预后的潜在生物标志物。

Objective：To investigate the role of DLG5 in clinical diagnosis of breast cancer by studying the rela-tionship between DLG5 and 34βE12. Methods ：The expression of DLG5 in different stages and different 34βE12 status breast cancer were measured by immunohistochemistry technical analysis. Inmmnoblotting analysis of the relation-ship between DLG5 and 3413E12 after knockdown of DLG5 expression was done by lentivirus-mediated shRNA inter-ference. Results ：DLG5 was highly expressed in low-grade breast cancer, but its expression was reduced or lost in high-grade breast cancer. DLG5 expression showed a positive correlation with ER/PR and 34βE12 status in breast cancer. Knockdown of DLG5 expression inhibited 34βE12 expression in MCF10A cells. Conclusion： DLG5 can be used in clinical diagnosis of breast cancer and might be a biomarker of ER/PR positive breast cancer treatment and prognosis.